ment of molecular biology, biochemistry and oncology in the past decade, scientists have taken great efforts identifying gene and/or biochemical markers that are associated with tumorigenesis, and several screening approaches have been developed and used in clinic. These applications have greatly benefited the early detection and remarkably reduced cancer deaths. Recently, Batlle group from Spain identified EphB2 as an intestinal stem cell (ISC) marker gene that can be used to identify colorectal cancer stem cells and predict colorectal cancer relapse (Merlos-Suárez et al., 2011) .
ISCs reside at the base of mucosal invaginations (crypt). Their progeny transient amplifying cells move upward as they proliferate through mitosis until get close to intestinal lumen, where cells undergo cell cycle arrest and terminal differentiation. ISCs are essential for the tissue regeneration in intestine. However, they also exhibit relatively high efficiency to develop colorectal tumors upon mutations of genes in Wnt signaling pathway, which are suggested to activate intestinal tumorigenesis. EphB2 is a receptor tyrosine kinase that is regulated by Wnt pathway. Targeted deletion of EphB2, EphB3 or their ligand ephrin-B1 in mouse caused intestinal cell compartmentalization defects (Batlle et al., 2002; Cortina et al., 2007) , indicating the essential role of EphB signaling in cell positioning in crypts.
EphB2 is expressed in a decreasing trend from the crypt base toward the differentiated cell compartment in intestine lumen, corresponding to intestinal stem cell marker, Lgr5 (Batlle et al., 2002 
